Wednesday, January 29, 2014

BioLamina's LN-521 removes problems delaying stem cell therapy

BioLamina (Stockholm, Sweden) is a company developing, producing and marketing tools that help scientists handle different types of primary cells including stem cells. One of the main products is LN-521™, a human recombinant laminin-521, which has now shown to solve several critical technical problems that have been delaying or even blocking the development of cell therapy and regenerative medicine.Only a few clinical trials have so far been performed with cells of embryonic stem cell origin since they were first isolated in 1998.

No comments:

Post a Comment